In last trading session, Immunome Inc (NASDAQ:IMNM) saw 0.55 million shares changing hands with its beta currently measuring 1.81. Company’s recent per share price level of $12.98 trading at $0.44 or 3.51% at ring of the bell on the day assigns it a market valuation of $779.50M. That closing price of IMNM’s stock is at a discount of -138.52% from its 52-week high price of $30.96 and is indicating a premium of 46.61% from its 52-week low price of $6.93. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.49 million shares which gives us an average trading volume of 605.12K if we extend that period to 3-months.

For Immunome Inc (IMNM), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.56 in the current quarter.

Immunome Inc (NASDAQ:IMNM) trade information

Upright in the green during last session for gaining 3.51%, in the last five days IMNM remained trading in the green while hitting it’s week-highest on Wednesday, 11/06/24 when the stock touched $12.98 price level, adding 4.98% to its value on the day. Immunome Inc’s shares saw a change of 21.31% in year-to-date performance and have moved 11.99% in past 5-day. Immunome Inc (NASDAQ:IMNM) showed a performance of 9.35% in past 30-days. Number of shares sold short was 10.92 million shares which calculate 12.78 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 33 to the stock, which implies a rise of 60.67% to its current value. Analysts have been projecting 23 as a low price target for the stock while placing it at a high target of 35. It follows that stock’s current price would drop -77.2% in reaching the projected high whereas dropping to the targeted low would mean a loss of -77.2% for stock’s current value.

Immunome Inc (IMNM) estimates and forecasts

Statistics highlight that Immunome Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -16.26% of value to its shares in past 6 months, showing an annual growth rate of -219.08% while that of industry is 16.60. Apart from that, the company came lowering its revenue forecast for fiscal year 2024. This year revenue growth is estimated to fall -40.10% from the last financial year’s standing.

6 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 2.13M for the same. And 6 analysts are in estimates of company making revenue of 2.83M in the next quarter. Company posted 3.56M and 3.83M of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -48.48% during past 5 years.

Immunome Inc (NASDAQ:IMNM)’s Major holders

Insiders are in possession of 16.81% of company’s total shares while institution are holding 78.13 percent of that, with stock having share float percentage of 93.92%. Investors also watch the number of corporate investors in a company very closely, which is 78.13% institutions for Immunome Inc that are currently holding shares of the company. FMR LLC is the top institutional holder at IMNM for having 4.21 million shares of worth $50.95 million. And as of 2024-06-30, it was holding 40.8477 of the company’s outstanding shares.

The second largest institutional holder is BLACKROCK INC., which was holding about 3.76 million shares on 2024-06-30. The number of shares represents firm’s hold over 36.4624 of outstanding shares, having a total worth of $45.48 million.